<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>468 severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (SAA) patients registered in the EBMT-SAA registry who did not undergo bone marrow transplantation and were treated with immunosuppressive therapy (IS; 96% of patients received ATG) were evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>Their median age was 23 years (range 1-73) at initial IS therapy, 59% were males; in 69% the aetiology of SAA was idiopathic </plain></SENT>
<SENT sid="2" pm="."><plain>Of these 468 patients, 245 had a follow-up of less than 2 years after IS 166/245 died, 71/245 are still alive, 8/245 are lost to follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>Of 223 patients who survived greater than or equal to 2 years (LTS long-term survivors), 191 are alive, 21 died greater than 2 years and 11 are lost </plain></SENT>
<SENT sid="4" pm="."><plain>Median follow-up of 223 LTS was 4.1 years (range 2.0-10.9) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparison of 166 patients who died less than 2 years and 223 LTS revealed no difference at time of initial IS therapy as regards sex, duration of AA, or its aetiology, but the age distribution and, in particular, severity of SAA differed significantly: more LTS were between 21 and 40 years old (44% v </plain></SENT>
<SENT sid="6" pm="."><plain>32%, P less than 0.02), less LTS had reticulocytes less than 20 x 10(9)/l (63% v </plain></SENT>
<SENT sid="7" pm="."><plain>80%, P less than 0.001), polymorphonuclear granulocytes (PMN) less than 0.2 x 10(9)/l (30% v </plain></SENT>
<SENT sid="8" pm="."><plain>57%, P less than 0.001), haemorrhages (58% v </plain></SENT>
<SENT sid="9" pm="."><plain>79%, P less than 0.002) and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (30% v </plain></SENT>
<SENT sid="10" pm="."><plain>49%, P less than 0.005) at time of IS </plain></SENT>
<SENT sid="11" pm="."><plain>A gradual improvement of blood counts was seen in patients alive greater than or equal to 2 years after IS </plain></SENT>
<SENT sid="12" pm="."><plain>At 2 years after IS 80% had a <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> and PMN greater than 0.5 x 10(9)/l, but only after 5 years 80% of cases had platelets greater than 50 x 10(9)/l </plain></SENT>
<SENT sid="13" pm="."><plain>Development of clonal disease was reported of 31 LTS: 19 developed <z:e sem="disease" ids="C0024790" disease_type="Disease or Syndrome" abbrv="PNH">paroxysmal nocturnal haemoglobinuria</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>), one <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, 11 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and of these 11 five subsequently <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="14" pm="."><plain>The majority of these patients (23/31) are still alive </plain></SENT>
<SENT sid="15" pm="."><plain>Actuarial mortality of LTS is 22% at 8 years, but so far no plateau was achieved </plain></SENT>
<SENT sid="16" pm="."><plain>It is concluded that SAA patients who become LTS following IS, show an improvement in haematological status but are probably not cured and are prone to develop clonal (malignant) disease </plain></SENT>
</text></document>